YMAB Total Current Assets vs Deferred Long Term Liab Analysis

YMAB Stock

USD 11.88 1.11 10.31%

Y MAbs financial indicator trend analysis is more than just analyzing Y mAbs Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Y mAbs Therapeutics is a good investment. Please check the relationship between Y MAbs Total Current Assets and its Deferred Long Term Liab accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Total Current Assets vs Deferred Long Term Liab

Total Current Assets vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Y mAbs Therapeutics Total Current Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Y MAbs' Total Current Assets and Deferred Long Term Liab is -0.24. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Y mAbs Therapeutics, assuming nothing else is changed. The correlation between historical values of Y MAbs' Total Current Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Y mAbs Therapeutics are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Current Assets i.e., Y MAbs' Total Current Assets and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

-0.24

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Y MAbs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Y mAbs Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

As of November 29, 2024, Selling General Administrative is expected to decline to about 33.2 M. In addition to that, Tax Provision is expected to decline to about 308.6 K

	2023	2024 (projected)
Depreciation And Amortization	735K	540.3K
Interest Income	687.7K	979.4K

Depreciation And Amortization Interest Income

Y MAbs fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Assets	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Property Plant And Equipment Net
Total Assets		0.74	0.83	1.0	0.43	0.99	-0.96	-0.71	0.87	0.98	0.98	0.89	0.56	0.78	0.63	0.85	0.88	0.86	0.82	1.0	0.89	0.45	-0.27	0.87	0.83	0.73
Other Current Liab	0.74		0.96	0.68	0.66	0.71	-0.59	-0.96	0.86	0.61	0.61	0.9	0.91	0.83	0.81	0.97	0.84	0.97	0.96	0.71	0.9	0.42	-0.4	0.47	0.38	0.62
Total Current Liabilities	0.83	0.96		0.77	0.68	0.78	-0.7	-0.92	0.96	0.73	0.73	0.91	0.89	0.76	0.79	0.95	0.92	0.97	1.0	0.8	0.91	0.51	-0.31	0.57	0.49	0.76
Total Stockholder Equity	1.0	0.68	0.77		0.37	1.0	-0.98	-0.66	0.83	0.99	0.99	0.86	0.49	0.76	0.58	0.8	0.84	0.82	0.76	1.0	0.86	0.43	-0.25	0.89	0.86	0.7
Other Liab	0.43	0.66	0.68	0.37		0.39	-0.29	-0.72	0.56	0.33	0.33	0.68	0.72	0.58	0.9	0.68	0.78	0.68	0.74	0.39	0.68	0.16	-0.31	0.12	0.05	0.72
Net Tangible Assets	0.99	0.71	0.78	1.0	0.39		-0.96	-0.68	0.81	0.98	0.98	0.88	0.51	0.8	0.62	0.83	0.85	0.84	0.78	0.99	0.88	0.42	-0.28	0.88	0.84	0.69
Net Debt	-0.96	-0.59	-0.7	-0.98	-0.29	-0.96		0.51	-0.78	-0.98	-0.98	-0.78	-0.36	-0.66	-0.48	-0.73	-0.79	-0.73	-0.69	-0.97	-0.78	-0.45	0.03	-0.92	-0.91	-0.71
Retained Earnings	-0.71	-0.96	-0.92	-0.66	-0.72	-0.68	0.51		-0.82	-0.59	-0.59	-0.89	-0.93	-0.82	-0.85	-0.92	-0.84	-0.95	-0.94	-0.68	-0.9	-0.3	0.61	-0.39	-0.3	-0.6
Accounts Payable	0.87	0.86	0.96	0.83	0.56	0.81	-0.78	-0.82		0.81	0.81	0.85	0.77	0.66	0.63	0.86	0.89	0.89	0.94	0.85	0.85	0.52	-0.2	0.65	0.59	0.76
Cash	0.98	0.61	0.73	0.99	0.33	0.98	-0.98	-0.59	0.81		1.0	0.81	0.42	0.69	0.52	0.74	0.82	0.76	0.72	0.99	0.81	0.43	-0.2	0.9	0.88	0.7
Cash And Short Term Investments	0.98	0.61	0.73	0.99	0.33	0.98	-0.98	-0.59	0.81	1.0		0.81	0.42	0.69	0.52	0.74	0.82	0.76	0.72	0.99	0.81	0.43	-0.2	0.9	0.88	0.7
Common Stock Total Equity	0.89	0.9	0.91	0.86	0.68	0.88	-0.78	-0.89	0.85	0.81	0.81		0.79	0.93	0.86	0.97	0.91	0.97	0.93	0.87	1.0	0.31	-0.39	0.62	0.55	0.73
Common Stock Shares Outstanding	0.56	0.91	0.89	0.49	0.72	0.51	-0.36	-0.93	0.77	0.42	0.42	0.79		0.66	0.83	0.85	0.76	0.86	0.9	0.52	0.79	0.42	-0.47	0.28	0.19	0.65
Short Term Investments	0.78	0.83	0.76	0.76	0.58	0.8	-0.66	-0.82	0.66	0.69	0.69	0.93	0.66		0.78	0.88	0.75	0.87	0.79	0.76	0.93	0.16	-0.53	0.46	0.39	0.47
Non Current Liabilities Total	0.63	0.81	0.79	0.58	0.9	0.62	-0.48	-0.85	0.63	0.52	0.52	0.86	0.83	0.78		0.86	0.86	0.85	0.84	0.59	0.86	0.26	-0.43	0.37	0.29	0.77
Capital Surpluse	0.85	0.97	0.95	0.8	0.68	0.83	-0.73	-0.92	0.86	0.74	0.74	0.97	0.85	0.88	0.86		0.91	0.99	0.97	0.82	0.96	0.41	-0.33	0.61	0.53	0.72
Other Current Assets	0.88	0.84	0.92	0.84	0.78	0.85	-0.79	-0.84	0.89	0.82	0.82	0.91	0.76	0.75	0.86	0.91		0.93	0.94	0.86	0.91	0.48	-0.28	0.68	0.62	0.89
Other Stockholder Equity	0.86	0.97	0.97	0.82	0.68	0.84	-0.73	-0.95	0.89	0.76	0.76	0.97	0.86	0.87	0.85	0.99	0.93		0.98	0.83	0.97	0.4	-0.39	0.61	0.53	0.72
Total Liab	0.82	0.96	1.0	0.76	0.74	0.78	-0.69	-0.94	0.94	0.72	0.72	0.93	0.9	0.79	0.84	0.97	0.94	0.98		0.79	0.93	0.49	-0.33	0.55	0.48	0.78
Total Current Assets	1.0	0.71	0.8	1.0	0.39	0.99	-0.97	-0.68	0.85	0.99	0.99	0.87	0.52	0.76	0.59	0.82	0.86	0.83	0.79		0.87	0.45	-0.24	0.88	0.85	0.72
Common Stock	0.89	0.9	0.91	0.86	0.68	0.88	-0.78	-0.9	0.85	0.81	0.81	1.0	0.79	0.93	0.86	0.96	0.91	0.97	0.93	0.87		0.3	-0.43	0.62	0.55	0.72
Other Assets	0.45	0.42	0.51	0.43	0.16	0.42	-0.45	-0.3	0.52	0.43	0.43	0.31	0.42	0.16	0.26	0.41	0.48	0.4	0.49	0.45	0.3		0.11	0.54	0.52	0.56
Deferred Long Term Liab	-0.27	-0.4	-0.31	-0.25	-0.31	-0.28	0.03	0.61	-0.2	-0.2	-0.2	-0.39	-0.47	-0.53	-0.43	-0.33	-0.28	-0.39	-0.33	-0.24	-0.43	0.11		0.03	0.07	0.0
Net Invested Capital	0.87	0.47	0.57	0.89	0.12	0.88	-0.92	-0.39	0.65	0.9	0.9	0.62	0.28	0.46	0.37	0.61	0.68	0.61	0.55	0.88	0.62	0.54	0.03		1.0	0.67
Net Working Capital	0.83	0.38	0.49	0.86	0.05	0.84	-0.91	-0.3	0.59	0.88	0.88	0.55	0.19	0.39	0.29	0.53	0.62	0.53	0.48	0.85	0.55	0.52	0.07	1.0		0.63
Property Plant And Equipment Net	0.73	0.62	0.76	0.7	0.72	0.69	-0.71	-0.6	0.76	0.7	0.7	0.73	0.65	0.47	0.77	0.72	0.89	0.72	0.78	0.72	0.72	0.56	0.0	0.67	0.63

Click cells to compare fundamentals

Y MAbs Account Relationship Matchups

Y MAbs fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	216.4M	132.0M	212.8M	141.5M	127.9M	150.1M
Other Current Liab	4.6M	6.2M	10.8M	12.4M	12.3M	7.2M
Total Current Liabilities	13.6M	19.5M	27.9M	28.3M	20.1M	17.8M
Total Stockholder Equity	198.9M	105.8M	180.1M	109.2M	101.0M	127.8M
Other Liab	2.2M	4.7M	3.0M	3.1M	3.5M	3.0M
Net Tangible Assets	198.9M	105.8M	178.4M	106.2M	122.2M	129.5M
Net Debt	(204.9M)	(110.7M)	(177.9M)	(104.0M)	(77.2M)	(81.1M)
Retained Earnings	(165.9M)	(285.2M)	(340.5M)	(436.0M)	(457.5M)	(434.6M)
Accounts Payable	8.5M	9.4M	13.6M	14.2M	6.1M	9.0M
Cash	207.1M	114.6M	181.6M	105.8M	78.6M	129.7M
Non Current Assets Total	4.4M	9.7M	10.5M	11.0M	16.8M	17.6M
Non Currrent Assets Other	370K	3.3M	3.2M	5.7M	12.5M	13.1M
Cash And Short Term Investments	207.1M	114.6M	181.6M	105.8M	78.6M	129.7M
Common Stock Shares Outstanding	35.2M	40.1M	43.2M	43.7M	43.6M	41.4M
Liabilities And Stockholders Equity	216.4M	132.0M	212.8M	141.5M	127.9M	150.1M
Non Current Liabilities Total	3.9M	6.7M	4.8M	4.0M	6.8M	4.5M
Capital Surpluse	225.4M	364.7M	391.6M	519.2M	597.1M	304.2M
Other Current Assets	4.8M	7.7M	7.5M	5.5M	5.0M	4.9M
Other Stockholder Equity	364.7M	391.6M	519.2M	543.9M	558.0M	379.6M
Total Liab	17.5M	26.2M	32.7M	32.2M	26.9M	22.3M
Total Current Assets	212.0M	122.4M	202.3M	130.4M	111.1M	142.8M
Accumulated Other Comprehensive Income	50K	(526K)	1.4M	1.3M	449K	349.7K
Other Assets	370K	7.9M	206.9M	5.7M	1.0	0.95
Net Invested Capital	198.9M	105.8M	180.1M	109.2M	101.0M	104.9M
Net Working Capital	198.4M	102.8M	174.4M	102.2M	91.0M	102.2M
Property Plant And Equipment Net	4.0M	6.4M	5.7M	2.3M	1.6M	1.6M
Property Plant And Equipment Gross	4.0M	6.4M	5.7M	2.3M	1.6M	1.6M
Non Current Liabilities Other	242K	6.7M	4.8M	802K	864K	820.8K
Property Plant Equipment	4.0M	1.8M	5.7M	2.3M	2.7M	3.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:

How To Invest In YMAB

Details

Is YMAB Stock a good investment?

Details

What is Y MAbs' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.54)

Revenue Per Share

1.921

Quarterly Revenue Growth

(0.1)

Return On Assets

(0.12)

Return On Equity

(0.25)

The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

YMAB Total Current Assets vs Deferred Long Term Liab Analysis

Total Current Assets vs Deferred Long Term Liab

Total Current Assets vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Total Current Assets

Deferred Long Term Liab

Y MAbs fundamental ratios Correlations

Y MAbs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Y MAbs fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.96	Net Tangible Assets
Retained Earnings	- 0.96	Other Current Liab